DOCSLIB.ORG

The Importance of COX-2 Inhibition for Aspirin Induced Asthma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Importance of COX-2 Inhibition for Aspirin Induced Asthma S54 Thorax 2000;55 (Suppl 2):S54–S56 Thorax: first published as 10.1136/thorax.55.suppl_2.S54 on 1 October 2000. Downloaded from The importance of COX-2 inhibition for aspirin induced asthma Alan Bennett There have been recent reviews of aspirin “specific” is used here to denote that the activ- induced asthma (AIA),12 the use of the ity is (usually) much greater against COX-2 COX-2 preferential inhibitor nimesulide in than against COX-1. Two drugs with a asthmatic patients intolerant to non-steroidal “preferential” status are nimesulide and mel- anti-inflammatory drugs (NSAIDs),3 and of oxicam, whereas two drugs that probably nimesulide in general.45 This paper discusses deserve the title “specific” are rofecoxib and the importance of inhibiting prostaglandin E2 celecoxib. (PGE2) synthesis in AIA, and the relative Nimesulide (4-nitro-2-phenoxymethane- safety of NSAIDs that preferentially inhibit sulphonanilide) is particularly important in COX-2. AIA because several studies have shown that it Aspirin and other NSAIDs cause broncho- is tolerated by most patients with the disorder constriction in about 10% of asthmatic to about the same extent as paracetamol. This subjects but NSAIDs relieve asthma in about sulphonanilide NSAID, which is eVective in 0.3%.2 This variability helps to show the com- treating a wide spectrum of inflammatory and plexity of the problem. Prostaglandins in painful conditions,7 was first marketed in 1985 human lung are formed by various tissues and and 10 years later it was found to be a cells, including bronchial muscle, epithelium, preferential inhibitor of COX-2.89Because it is and inflammatory cells,12 so the inhibition of not marketed in the USA, Japan, or the UK, prostaglandin formation can have numerous nimesulide is not well known in some parts of eVects. In addition, the prostanoids (prosta- the world. Nevertheless, in the 50 countries glandins and thromboxanes) formed have dif- where it is now sold, nimesulide is often the ferent, and sometimes opposite, eVects on the first or second NSAID in the local market, and lungs. Furthermore, NSAIDs may alter the it is fifth worldwide despite being absent from synthesis of various prostaglandins diVerently the largest markets. in patients with AIA—for example, aspirin In every study of COX selectivity nimesulide reduces the synthesis of PGE2 but not of the was more potent against COX-2 than COX-1. 6 bronchoconstrictors PGD2 and PGF2á. Inhi- However, as with all NSAIDs, its COX-1/ bition of PGE2 synthesis seems to be particu- COX-2 ratio varies in diVerent reports (from 9 larly important in AIA for several reasons: about 4.5 to 2500 in favour of COX-2). http://thorax.bmj.com/ PGE2 can relax bronchial muscle, inhibit the Factors influencing the ratio include the formation or release of various broncho- enzyme source, cell type, substrate concentra- constrictor agents such as leukotrienes and tion, and incubation time. histamine (levels of which are raised in Our own investigations were on COX-1 and patients with AIA), and PGE2 administered COX-2 sheep pure enzymes, and human as an aerosol inhibits aspirin induced gastric mucosa (constitutive COX-1) and bronchoconstriction.12 leucocytes (induced COX-2).8 We found that Since PGE2 and other prostanoids are COX-1 from sheep seminal vesicles was not formed by both constitutive COX-1 and inhibited by nimesulide, in contrast to the on September 26, 2021 by guest. Protected copyright. induced COX-2, the eVect on the lung may concentration-related inhibition by indometh- partly reflect the relative activities of each acin, naproxen, piroxicam, ibuprofen, tolmetin, NSAID on the enzymes. Generally, in various and diclofenac. COX-2 from sheep placenta tissues and organs such as the gastrointestinal was blocked by all the NSAIDs. In our human mucosa and kidney, COX-1 produces prosta- in vitro studies nimesulide blocked COX-2 in glandins that have physiological protective leucocytes, but only weakly inhibited COX-1 in roles, whereas COX-2 induced at sites of isolated gastric mucosa. Similarly, with human inflammation forms prostaglandins that subjects nimesulide inhibited leucocyte contribute to the disease. It is generally COX-2 to a considerable extent but had little agreed that blocking COX-1 can damage the eVect on COX-1 in the gastric mucosa and stomach and kidneys, at least when other fac- platelets.10 tors are involved, and perhaps this applies to the lungs. Nimesulide Academic Department Since nimesulide was initially thought to act of Surgery, The Rayne mainly by non-prostaglandin mechanisms Institute, Guy’s, King’s COX-2/COX-1 inhibition in relation to and St Thomas’ AIA (before it was realised that tissue containing Medical School, Examination of the relative importance of COX-1 was used to measure inhibition of London SE5 9NU, UK COX enzymes in AIA can be partly assessed prostaglandin synthesis11), nimesulide was A Bennett from studies using preferential COX-2 inhibi- tested in patients who could not tolerate tors. The term “preferential” is used here to other NSAIDs. The studies summarised in Correspondence to: Professor A Bennett denote activity that is somewhat greater against table 1 show that nimesulide can be tolerated [email protected] COX-2 than against COX-1, whereas the term by most patients with AIA. It can usually www.thoraxjnl.com Importance of COX-2 inhibition for aspirin induced asthma S55 Thorax: first published as 10.1136/thorax.55.suppl_2.S54 on 1 October 2000. Downloaded from Table 1 Tolerance data on nimesulide in AIA Thus, the usual lack of bronchial problems with nimesulide in patients with AIA might Patients tolerating Nimesulide dose (mg) nimesulide (%) Reference result partly from these other pharmacological actions. Meloxicam has also been reported to 100 20/20 (100%) 12 have non-prostaglandin activity and this might 100 20/20 (100%) 13 400 18/20 (90%) 13 become relevant to the present discussion if the 200 46/50 (92%) 14 drug is found in larger studies to be relatively 100 7/12 (58%) 15 safe in AIA. The picture should be clarified in Nimesulide was started at a low dose and then increased to the due course by examination of the selective amount shown. The usual anti-inflammatory dose is 100 mg COX-2 inhibitors rofecoxib and celecoxib. It twice daily. In the study by Bianco et al13 the 20 patients were the same in the 100 mg and 400 mg groups. remains to be seen how much COX-1 activity is needed to allow production of prostaglandins Table 2 Tolerance data on nimesulide in patients with other for physiological functions, and whether a symptoms of NSAID intolerance small inhibition of COX-1 added to a stronger eVect on COX-2 might be beneficial in reliev- Patients tolerating Nimesulide dose (mg) nimesulide (%) Reference ing inflammatory processes that contribute to asthma and other diseases. 500 (over 84 h) 86/92 (93%) 16 200 39/42 (93%) 17 100 270/284 (95%) 18 1 Szczeklik A, Stevenson DD. Aspirin-induced asthma: 200 83/87 (95%) 19 advances in pathogenesis and management. J Allergy Clin 200 415/429 (97%) 20 Immunol 1999;104:5–13. 175 14/15 (93%) 21 2 Gryglewski RJ. Aspirin-induced asthma and cyclooxygen- 100 7/8 (88%) 15 ases. In: Vane J, Botting J, eds. Selective COX-2 inhibitors. Pharmacology, clinical eVects and therapeutic potential. Wil- Nimesulide was started at a low dose and then increased to the liam Harvey Press and Kluwer Academic Publishers, 1998: 99–107. amount shown. The usual anti-inflammatory dose is 100 mg 3 Senna GE, Passalacqua G, Andri G, et al. Nimesulide in the twice daily. Symptoms in the few patients showing some intoler- treatment of patients intolerant of aspirin and other ance to nimesulide were often mild. NSAIDs. Drug Safety 1996;14:94–103. 4 Bennett A. Overview of nimesulide. Rheumatology 1999; 38(Suppl 1):1–3. be given without any problems to patients 5 Bennett A, Villa G. Nimesulide: a nonsteroidal anti- inflammatory drug that preferentially inhibits with other symptoms of NSAID intolerance cyclooxygenase-2, and has various unique pharmacological such as urticaria and/or angio-oedema activities. Expert Opinion on Pharmacotherapy 2000;1:277– (table 2). 86. 6 Szczeklik A, Sladek K, Dworski R, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin- sensitive asthmatics. Am J Respir Crit Care Med 1996;154: 1608–14. Meloxicam 7 Bennett A, Berti F, Ferreira SH. Nimesulide: a multifacto- Only one small study has been reported on the rial therapeutic approach to the inflammatory process? Drugs 1993;46 (Suppl 1). use of meloxicam in patients with AIA. In five 8 Tavares IA, Bishai PM, Bennett A, Activity of nimesulide on NSAID intolerant patients dyspnoea occurred constitutive and inducible cyclo-oxygenases. Arzneimittel- Forschung 1995;45:1093–6. in two with aspirin and two with ketoprofen, 9 Famaey J-P.In vitro and in vivo pharmacological evidence of but three of these four had no dyspnoea with selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm Res 1997;46:437–46. http://thorax.bmj.com/ 11 mg meloxicam (therapeutic dose 7.5– 10 Shah AA, Murray FE, Fitzgerald DJ. The in vivo assessment 15 mg daily).22 of nimesulide cyclooxygenase-2 selectivity. Rheumatology 1999;38(Suppl 1):19–23. 11 Magni E. The eVect of nimesulide on prostanoid formation. Drugs 1993;46(Suppl 1):10–14. Celecoxib and rofecoxib 12 Robuschi M, Refini M, Sturman et al. La nimesulide non induce asma in pazienti asmatici FANS intolleranti. These new selective COX-2 inhibitors have not Proceedings of an International Symposium on Advances in yet been examined in AIA and are currently Pneumology and Cardiology. Bologna: Monduzzi Publishers, 1987: 431–5.
Load more

Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Nimesulide: Patients Still Exposed to a Risk of Severe Hepatitis
    Translated from Rev Prescrire January 2011; 31 (327): 22-23 Nimesulide: patients still exposed to a risk of severe hepatitis Abstract imesulide, a nonsteroidal anti- Severe liver damage at standard N inflammatory drug (NSAID), has doses, especially in young women. In Nimesulide, a nonsteroidal anti- been on the French market since 2007, the Italian Medicines Agency inflammatory drug (NSAID) that has 1998 (1). It is neither more effective nor released Italian pharmacovigilance data been marketed in France since 1998, is better tolerated than many other showing that hepatic adverse effects rep- neither more effective nor better tol- NSAIDs, and has been shown to cause resented 13.8% of reports implicating erated than other NSAIDs. potentially life-threatening liver da- nimesulide, compared to only 1.4% for mage (1-5). ibuprofen and 2.8% for diclofenac (3). Many reports and reviews published What is known concerning the hepatic The CHMP report published in 2008 by drug regulatory agencies in Spain, adverse effects of nimesulide in early included similar findings. Among the Ireland and Italy have warned of the 2011? 574 reports implicating nimesulide record- hepatic adverse effects of nimesulide. ed in the European EudraVigilance phar- In early 2008, 17 cases of nimesulide- An increasing number of reports of macovigilance database, the proportion of induced liver damage requiring trans- liver damage. Soon after it was first mar- hepatic disorders (cholestasis, jaundice, plantation had been reported in Ire- keted, cases of hepatitis were attributed liver failure, and hepatitis) was higher land, Italy, Spain, Finland and France. to nimesulide, including a case of fulmi- than with cox-2 inhibitors.
    [Show full text]
  • White Paper on Nimesulide Pharmacologic Category
    White paper on Nimesulide Pharmacologic Category : Analgesic, Nonsteroidal Anti-inflammatory Drug; Nonsteroidal Anti-inflammatory Drug (NSAID) Indications: Fever, Pain & Inflammation Duration: Can be safely prescribed upto 15 days. Adults: Oral: 100 mg twice daily. Children below 12 years: Not to be used. Product Availability: Product available in various countries; not currently available in the U.S. Dosage Forms: Tablet: 100 mg 1. Nimesulide has preferential selectivity for COX-2 over COX-1 in vivo at full therapeutic doses and induces less gastrointestinal damage than that seen with naproxen in the short term. [ Uptodate: Gut. 2001;48(3):339.] 2. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. The prevalence of atopy is increased in challenge-proven NSAID-intolerant patients. The atopic condition may represent an important risk factor for developing reactions to these drugs. Paracetamol and nimesulide are relatively safe alternative choices in those patients. [ Uptodate: Ann Allergy Asthma Immunol. 2000;84(1):101.] 3. Topical NSAIDs that are effective for chronic musculoskeletal pain in adults include diclofenac, ketoprofen (level 1 [likely reliable] evidence), ibuprofen, felbinac, and nimesulide (level 2 [mid-level] evidence) [DynaMed] 4. nimesulide may be associated with better efficacy than diclofenac for acute gout (level 2 [mid-level] evidence) [Ter Arkh 2007;79(5):35 ] 5. Nimesulide is safe in Crohn's disease [DynaMed: Clin Gastroenterol Hepatol 2006 Feb;4(2):196] 6. It is safe in ulcerative colitis { DynaMed Clin Gastroenterol Hepatol 2006 Feb;4(2):196, commentary can be found in Clin Gastroenterol Hepatol 2006 Feb;4(2):157] 7. Many PUBMED studies are available about its efficacy in primary dysmennhorea, acute dental pain, respiratory inflammatory conditions etc.
    [Show full text]
  • Effects of the European Restrictive Actions Concerning Nimesulide Prescription
    ANN IST SUPER SANITÀ 2010 | VOL. 46, NO. 2: 153-157 153 DOI: 10.4415/ANN_10_02_08 ES Effects of the European restrictive actions I concerning nimesulide prescription: a simulation study on hepatopathies ETHODOLOG M and gastrointestinal bleedings in Italy ND A Mauro Venegoni(a), Roberto Da Cas(b), Francesca Menniti-Ippolito(b) and Giuseppe Traversa(b) RCH A (a)Centro Regionale di Farmacovigilanza, Regione Lombardia, Milan, Italy (b) ESE Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, R Istituto Superiore di Sanità, Rome, Italy Summary. In 2002 and 2007 the European Medicines Agency (EMA) examined the signals of a greater risk of hepatopathies related to nimesulide use. In 2007 restrictive actions were adopted in Europe. Moreover, EMA initiated a new referral in February 2010. The objective of this paper is to evaluate the effects of the 2007 regulatory measures concerning nimesulide and to estimate the potential effect of further actions. Specifically, we carried out a simulation on the expected number of hospitalisations for hepatopathies and upper gastrointestinal bleedings (UGIBs) in Italy before and after the regulatory measures (2006 vs. 2009), taking into account the shifting of nimesulide prescriptions on other non steroidal anti-inflammatory drugs (NSAIDs). The expected figures of hospitalisation for hepatopathies and UGIBs for all NSAIDs were calculated on the basis of risk estimates reported in two epidemiological studies. The result of the simulation suggests that the im- plementation of the restrictive actions might prevent 79 events of liver injuries, but might increase UGIBs by 859 events. The simulation helped to clarify the effects on hepatopathies and UGIBs as a consequence of nimesulide restriction of use.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs Alter Nuclear Factor- Κβ in a Class Specific Manner
    Myers MJ et al. Treatment Dev Vet Pract 2020(1): 11-18. 10.33513/TDVP/2001-02 Treatments and Developments: Veterinary Practice OCIMUM Research Article Non-Steroidal Anti-Inflammatory Drugs Alter Nuclear Factor- κβ in A Class Specific Manner Abstract The capacity of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) to affect the NF-κβ dependent pathway was examined. The NSAIDs were co-cultured with RAW 264.7 cells transfected with a plasmid encoding Secreted Embryonic Alkaline Phosphatase (SEAP) under the control of NF-κβ. SEAP production was initiated by stimulating the cells with E. coli derived Lipopolysaccharide Michael J Myers*, Anne J Lewandowski and (LPS). Diclofenac, indomethacin, celecoxib, tolfenamic acid, flufenamic acid, Christine M Deaver and piroxicam inhibited SEAP production. Ketoprofen, phenylbutazone, Center for Veterinary Medicine, Office of Research aspirin, and acetaminophen did not affect SEAP production. TNFα stimulation Division of Applied Veterinary Research, USA of HEK293 cells transfected with a SEAP reporter gene under the control of NF-κβ was used to determine whether the NSAIDs were working directly on Received: 16 June 2020 the NF-κβ pathway or on TLR4 signaling. TNFα stimulated HEK293 cells Accepted: 20 July 2020 showed that diclofenac and flunixin inhibited SEAP production, but aspirin Version of Record Online: 31 July 2020 did not. Meloxicam and diclofenac both inhibited the amount of p65 released after LPS stimulation of the RAW 264.7 cells while flunixin did not affect Citation p65 release. Flunixin had no effect on an NF-κβ gel shift assay. These results demonstrate that NSAIDs in four of the six NSAID families can inhibit NF- Myers MJ, Lewandowski AJ, Deaver CM (2020) κβ pathway, albeit via different points in the pathway.
    [Show full text]
  • Anti-Proliferative Effects of Piroxicam and Nimesulide on A431 Human
    Int J Cancer Manag. 2017 April; 10(4):e7565. doi: 10.5812/ijcm.7565. Published online 2017 April 22. Research Article Anti-Proliferative Effects of Piroxicam and Nimesulide on A431 Human Squamous Carcinoma Cell Line Faezeh Khodaie,1 Yalda Khazaei-Poul,1 and Taraneh Moini-Zanjani1,* 1Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran *Corresponding author: Taraneh Moini-Zanjani, Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Koodakyar Street, Daneshjoo boulevard, Velenjak, Tehran, IR Iran. Tel/Fax: +98-21-22439969, Tel: +98-9123497094, E-mail: [email protected] Received 2016 June 15; Accepted 2017 March 08. Abstract Background: Skin cancer is one of the most common types of cancer worldwide and non-steroidal anti-inflammatory drugs (NSAIDs) have been proposed for prevention and treatment of a variety of cancers. Objectives: In this study we aimed to evaluate the cytotoxic effects of piroxicam (a non-selective cyclooxygenase (COX) inhibitor) and nimesulide (a highly selective COX-2 inhibitor) on A431 human squamous carcinoma cell line. Methods: Squamous carcinoma cell line (A431) was cultured in RPMI medium containing 10% FBS and penicillin-streptomycin at 37°C and 5% CO2. Cells were treated with different concentrations of piroxicam and nimesulide (100 - 1000 µmol/L) for 24, 48 and 72 hours (h). Anti-proliferative effects were determined using MTT colorimetric assay. Results: Piroxicam and nimesulide reduced cell viability in a time and concentration dependent manner. The most cytotoxic effect was produced in 72 hours incubation time. The IC50 value of nimesulide was significantly lower than piroxicam in 24 and 72 hours, but not in 48 hours treatment duration.
    [Show full text]
  • Indomethacin in Pregnancy: Applications and Safety
    Original Article 175 Indomethacin in Pregnancy: Applications and Safety Gael Abou-Ghannam, M.D. 1 Ihab M. Usta, M.D. 1 Anwar H. Nassar, M.D. 1 1 Department of Obstetrics and Gynecology, American University of Address for correspondence and reprint requests Anwar H. Nassar, Beirut Medical Center, Hamra, Beirut, Lebanon M.D., American University of Beirut Medical Center, P.O. Box 113-6044/B36, Hamra 110 32090, Beirut, Lebanon (e-mail: [email protected]). Am J Perinatol 2012;29:175–186. Abstract Preterm labor (PTL) is a major cause of neonatal morbidity and mortality worldwide. Among the available tocolytics, indomethacin, a prostaglandin synthetase inhibitor, has been in use since the 1970s. Recent studies have suggested that prostaglandin synthetase inhibitors are superior to other tocolytics in delaying delivery for 48 hours and 7 days. However, increased neonatal complications including oligohydramnios, Keywords renal failure, necrotizing enterocolitis, intraventricular hemorrhage, and closure of the ► indomethacin patent ductus arteriosus have been reported with the use of indomethacin. Indometh- ► tocolysis acin has been also used in women with short cervices as well as in those with idiopathic ► preterm labor polyhydramnios. This article describes the mechanism of action of indomethacin and its ► short cervix clinical applications as a tocolytic agent in women with PTL and cerclage and its use in ► polyhydramnios the context of polyhydramnios. The fetal and neonatal side effects of this drug are also ► fetal side effects summarized and guidelines for its use are proposed. Preterm labor (PTL) is a major cause of neonatal morbidity in women with PTL and cerclage and its use in the context of and mortality worldwide.1 Care of premature infants has polyhydramnios.
    [Show full text]
  • Nimesulide for Painful Osteoarthritis
    For reprint orders, please contact: DRUG EVALUATION [email protected] Nimesulide for painful osteoarthritis Mauro Bianchi Osteoarthritis is one of the most common joint disorders in the world. It is costly and a major University of Milan, School of cause of pain and disability, especially in the elderly. The severity of pain often calls for Medicine, Department of Pharmacology, Via Vanvitelli, treatment with nonsteroidal anti-inflammatory drugs. Worldwide experience with nimesulide 32, 20129 Milano, Italy shows that this nonsteroidal anti-inflammatory drug has a number of pharmacological Tel.: +39 025 031 6930; properties that may make it favorable in the treatment of joint diseases. In recent years, Fax: +39 025 031 6949; several controlled studies have been carried out in order to investigate its analgesic effects in [email protected] patients with OA. The objective of this article is to review some of the features of osteoarthritis and to identify the role of nimesulide as a drug particularly tailored for the treatment of painful osteoarthritis. Osteoarthritis (OA) is one of the most common Rheumatism (EULAR) [4] and the American Col- forms of musculoskeletal disorder encountered lege of Rheumatology (ACR) Recommendations worldwide, particularly in Western populations. [11]. However, the severity of pain often requires A recent WHO report on the global burden of treatment with nonsteroidal antiinflammatory disease indicates that OA is likely to become one drugs (NSAIDs), which are the drugs preferred by of the most important causes of disability in many patients with OA [12]. Indeed, NSAIDs are both women and men [1]. The prevalence of OA the drug most commonly used by many doctors increases with age, affecting a large proportion of for the management of pain in OA patients, in elderly people [2].
    [Show full text]
  • The Selective Cyclooxygenase-2 Inhibitor Nimesulide Prevents Helicobacter Pylori-Associated Gastric Cancer Development in a Mouse Model
    Vol. 10, 8105–8113, December 1, 2004 Clinical Cancer Research 8105 The Selective Cyclooxygenase-2 Inhibitor Nimesulide Prevents Helicobacter pylori-Associated Gastric Cancer Development in a Mouse Model Ki Taek Nam,1 Ki-Baik Hahm,2 Sang-Yeon Oh,1 Results: Gastric tumors developed in 68.8% of mice Marie Yeo,2 Sang-Uk Han,2 Byeongwoo Ahn,3 that were given both MNU and H. pylori, whereas less than 10% developed gastric tumors when given either MNU or H. Young-Bae Kim,2 Jin Seok Kang,1 1 1 pylori alone. These findings indicate that H. pylori promotes Dong Deuk Jang, Ki-Hwa Yang, and carcinogen-induced gastric tumorigenesis. In mice treated Dae-Yong Kim4 with both MNU and H. pylori, nimesulide administration 1Department of General Toxicology, National Institute of substantially reduced H. pylori-associated gastric tumori- Toxicological Research, Korea Food and Drug Administration, Seoul; genesis, whereas substantial inductions of apoptosis were 2Genome Center for Gastroenterology, Ajou University School of 3 observed. In vitro studies demonstrated that nimesulide and Medicine, Suwon; Department of Veterinary Pathology, College of H. pylori when combined acted synergistically to induce Veterinary Medicine, Chungbuk National University, Cheongju; and 4Department of Veterinary Pathology, College of Veterinary Medicine more apoptosis than either alone. and School of Agricultural Biotechnology, Seoul National University, Conclusions: Our data show that nimesulide prevents Seoul, Korea H. pylori-associated gastric carcinogenesis, and suggest that COX-2 may be a target for chemoprevention of gastric cancer. ABSTRACT Purpose: Helicobacter pylori infection can lead to gastric INTRODUCTION cancer, and cyclooxygenase-2 (COX-2) is overexpressed in Helicobacter pylori causes chronic active gastritis and pep- the stomach during H.
    [Show full text]
  • Drug Allergies & Cross-Sensitivities
    DRUG ALLERGIES & CROSS-SENSITIVITIES A Presentation for HealthTrust Members June 2, 2020 Vasyl Zbyrak, PharmD, PGY-1Pharmacy Resident Saint Barnabas Medical Center Kristine A. Sobolewski, PharmD, BCPS, Preceptor 2 Speaker & Preceptor Disclosures The presenter and his preceptor have no real or perceived conflicts of interest related to this presentation. Note: This program may contain the mention of suppliers, brands, products, services or drugs presented in a case study or comparative format using evidence-based research. Such examples are intended for educational and informational purposes and should not be perceived as an endorsement of any particular supplier, brand, product, service or drug. 3 Learning Objectives Pharmacists & Nurses: Distinguish the different drug class allergies and their mechanism of action Describe the most common drug allergies and characteristics of an allergic reaction Recommend alternative treatment options based on the drug allergy profile while evaluating the potential risk for the patient 4 Learning Objectives Pharmacy Technicians Identify the characteristics of an allergic reaction and common drug allergies Recognize the names of potentially inappropriate medications based on allergies and cross-sensitivities 5 Patient Case JG is 62 YO female presenting to the ED with pain 9/10. Patient was ordered morphine 4 mg IV push. Pain was relieved, but a rash appeared on her face with some flushing. Patient is not complaining of any other symptoms or shortness of breath. 6 Is the patient experiencing a drug allergy? 7 Adverse Drug Reactions A general term utilized to encompass any unwanted reaction to a medication and are broadly divided into Type A and B reactions Type A Type B • Reactions occurring in most • Drug hypersensitivity that is patients that are common relatively uncommon, rare and predictable and mostly unpredictable • Involves potential overdose, • Involves intolerances, side effects and drug idiosyncrasy, pseudoallergy interactions and drug allergies Source: Celik G, et al.
    [Show full text]
  • Selectivity of Cyclo-Oxygenase Inhibitors in Human Pulmonary Epithelial and Smooth Muscle Cells
    Copyright #ERS Journals Ltd 2000 Eur Respir J 2000; 15: 751±756 European Respiratory Journal Printed in UK ± all rights reserved ISSN 0903-1936 Selectivity of cyclo-oxygenase inhibitors in human pulmonary epithelial and smooth muscle cells S.P. Range, L. Pang, E. Holland, A.J. Knox Selectivity of cyclo-oxygenase inhibitors in human pulmonary epithelial and smooth muscle Respiratory Medicine Unit, City Hospital, cells. S.P. Range, L. Pang, E. Holland, A.J. Knox. #ERS Journals Ltd 2000. Hucknall Road, Nottingham, NG5 1PB, ABSTRACT: Cyclo-oxygenase (COX) inhibitors may have a role in reducing in- UK flammation in asthma and other pulmonary diseases. COX inhibitors have different Correspondence: S.P. Range selectivities for the two COX isoenzymes (COX 1 and COX 2) which vary between Dept of Respiratory Medicine purified enzyme and intact cell preparations. The relative selectivity of COX inhi- University Hospital bitors has not been studied in human airway cells. Queen's Medical Centre A number of COX inhibitors in cultured human airway cells were compared which Nottingham NG7 2UH exclusively express either COX 1 (primary degree cultured human airway smooth UK muscle (HASM) cells) or COX 2 (A549 pulmonary epithelial cell-line) as measured by Fax: 44 1159424554 Western blotting. COX activity was assayed by prostaglandin (PG)E2 production following 30 min incubation with 5 mM arachidonic acid. Keywords: A549 cells . -1 airway smooth muscle COX activity in both cell types was similar; HASM cells 92.212.1 ng PGE2 mg . -1 asthma protein, A549 cells 87.724.4 ng PGE2 mg protein. In HASM cells the median -5 -6 cyclo-oxygenase inhibitory concentration (IC50) was >10 M for nimesulide, 3.2610 M for N-(2- cyclo- cyclo-oxygenase inhibitor -8 hexyloxy-4-nitrophenyl)-methanesulphonamide (NS398), 1.8610 M for flurbiprofen, prostaglandin E2 6.7610-9 M for indomethacin and >10-5 M for aspirin.
    [Show full text]
  • ANNEX III SUMMARY of PRODUCT CHARACTERISTICS Note
    ANNEX III SUMMARY OF PRODUCT CHARACTERISTICS Note: This SPC is the one that was annexed to the Commission Decision on this Article 31 referral for nimesulide containing medicinal products. The text was valid at that time. After the Commission Decision, the Member State competent authorities will update the product information as required. Therefore, this SPC may not necessarily represent the current text. CPMP/3086/03-REV.1 1 EMEA 2004 SUMMARY OF PRODUCT CHARACTERISTICS NIMESULIDE 100 MG TABLETS, SOLUBLE TABLETS, EFFERVESCENT TABLETS, COATED TABLETS, CAPSULES, HARD CAPSULES, NIMESULIDE 50/100 MG GRANULES OR POWDER FOR ORAL SUSPENSION NIMESULIDE 1%, 2% OR 5% ORAL SUSPENSION CPMP/3086/03-REV.1 2 EMEA 2004 1. NAME OF THE MEDICINAL PRODUCT <TRADENAME> 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet, soluble tablet, effervescent tablet, coated tablet, capsule, hard capsule contains 100mg nimesulide. Each sachet contains 50 or 100mg nimesulide. Oral suspension containing 10mg, 20mg or 50mg per ml. For excipients, see section 6.1 3. PHARMACEUTICAL FORM Tablet, soluble tablet, effervescent tablet or coated tablet: <Company-specific> Granules or powder for oral suspension: <Company-specific> Capsule, hard capsule: <Company-specific> Oral suspension: <Company-specific> 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of acute pain. Symptomatic treatment of painful osteoarthritis. Primary dysmenorrhoea. 4.2 Posology and method of administration <Nimesulide-containing medicinal products> should be used for the shortest possible duration, as required by the clinical situation. Adults: 100mg nimesulide tablets, soluble tablets, effervescent tablets, coated tablets, capsules, hard capsules, 50mg and 100mg granules or powder, 1%, 2% and 5% oral suspension: 100mg bid after meal Elderly: in elderly patients there is no need to reduce the daily dosage (see section 5.2).
    [Show full text]